Cargando…
Impact of Insulin Receptor Substrate‐1 rs956115 and CYP2C19 rs4244285 Genotypes on Clinical Outcome of Patients Undergoing Percutaneous Coronary Intervention
BACKGROUND: Insulin receptor substrate‐1 (IRS‐1) rs956115 is associated with vascular risk in patients with coronary artery disease and concomitant diabetes. CYP2C19*2 (rs4244285) modulates clopidogrel response and predicts the outcome of coronary artery disease. This study was designed to explore t...
Autores principales: | Zong, Jiaxin, Tang, Yingdan, Wang, Tong, Ullah, Inam, Xu, Ke, Wang, Jing, Chen, Pengsheng, Chen, Zengguang, Zhu, Tiantian, Chen, Jun, Li, Jimin, Wang, Fei, Yang, Lu, Fan, Yuansheng, Shi, Lu, Gong, Xiaoxuan, Eikelboom, John W., Zhao, Yang, Li, Chunjian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496289/ https://www.ncbi.nlm.nih.gov/pubmed/35929455 http://dx.doi.org/10.1161/JAHA.121.025058 |
Ejemplares similares
-
ABCA1 variants rs2230806 (R219K), rs4149313 (M8831I), and rs9282541 (R230C) are associated with susceptibility to coronary heart disease
por: Wang, Fangfang, et al.
Publicado: (2019) -
Associations Between CYP2B6 rs707265, rs1042389, rs2054675, and Hirschsprung Disease in a Chinese Population
por: Xu, Chao, et al.
Publicado: (2014) -
Distribution of alleles, genotypes and haplotypes of the CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) genes in the Malian population: Implication for pharmacogenetics
por: Kassogue, Yaya, et al.
Publicado: (2021) -
Polymorphisms in Phase I (CYP450) Genes CYP1A1 (rs4646421), CYP1B1 (rs1056836), CYP19A1 (rs749292) and CYP2C8 (rs1058930) and Their Relation to Risk of Breast Cancer: A Case-Control Study in Mazandaran Province in North of Iran
por: Golmohammadzadeh, Golpar, et al.
Publicado: (2019) -
Role of CYP19A1 Loci (rs28757157 and rs3751591) with Ischemic Stroke Risk in the Chinese Han Population
por: Huang, Kang, et al.
Publicado: (2023)